Carcinoid tumors, a rare form of neuroendocrine tumor, primarily emerge in the gastrointestinal tract or lungs. While often slow-growing and symptomatically silent, they can generate hormones triggering manifestations like flushing, diarrhea, and wheezing. Extensive research delves into unraveling the genetic mutations underlying carcinoid tumors, crucial for precise diagnosis and targeted therapies. Advanced imaging technologies, notably PET scans, play pivotal roles in their accurate detection and monitoring. Moreover, ongoing clinical trials explore innovative treatments, including peptide receptor radionuclide therapy (PRRT), aimed at enhancing outcomes for patients grappling with advanced carcinoid tumors. Through collaborative efforts, researchers and clinicians persist in advancing understanding and devising effective strategies for managing and treating these intricate tumors.



Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Nanomedicine in over 45,000 patients and no cancer
Thomas Jay Webster, Brown University, United States